SK Biopharmaceuticals Secures 128 NVIDIA B200 Units: "AI Transformation in Drug Development"
Focused Application to TR-AX
On September 2, SK Biopharmaceuticals announced that it has adopted 128 units of NVIDIA's Blackwell architecture-based AI accelerator, the B200. Leveraging this infrastructure, the company aims to strengthen its AI research capabilities specialized in bio and healthcare, intending to drive innovation throughout the drug development process and proactively create new business opportunities.
The computational performance of the 128 B200 units reaches 576 petaflops (PFLOPS) per second using FP8 precision, which is approximately 0.58 exaflops. This adoption was made possible through Haein, the first domestic data center cluster based on the B200, established by SK Telecom. SK Biopharmaceuticals plans to utilize GPU-as-a-Service (GPUaaS) to secure the necessary computational resources and advance its major AI research projects.
The secured computational resources will be primarily applied to 'TR-AX (Translational Research-AI Transformation),' referring to the AI transition of translational research. Translational research connects research findings from non-clinical phases, such as animal studies, to clinical results in humans. It plays a crucial role in assessing the success potential and enhancing the value of drug candidates during preclinical and early clinical stages.
Additionally, the company plans to apply its independently developed bio and healthcare-specialized foundation model to actual research projects, thereby advancing research capabilities across diseases, targets, and compounds. By utilizing large-scale computational resources, SK Biopharmaceuticals will also shorten the research cycle, from AI model training and inference to experimentation, analysis, and retraining. The goal is to enhance productivity across the entire drug development process, from candidate discovery to research decision-making.
Data security and governance will also be strengthened. Sensitive research data in the bio and healthcare sector will be managed within an infrastructure under the company’s control, enhancing security levels and providing a systematic foundation to respond to upcoming regulatory and compliance requirements.
SK Biopharmaceuticals plans to utilize its AI infrastructure not only for in-house research but also for collaborative research with external companies, research institutions, and universities. The company will expand the scope of the AI research platform to support industry-academia-research collaboration and seek joint studies and strategic partnerships. In the long term, SK Biopharmaceuticals is also considering turning its AI infrastructure and related technologies into separate business opportunities.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Lee Donghoon, CEO of SK Biopharmaceuticals, stated, "We made a preemptive investment based on our judgment that large-scale proprietary AI infrastructure is a core foundation for future competitiveness in drug development. With a global-class B200 infrastructure, we will further strengthen TR-AX — the key competence in early drug research and development — and maximize AI utilization throughout the drug development process to dramatically increase the speed and efficiency of our R&D."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.